Hepatitis C virus nonstructural protein 5B (NS5B) and host inosine monophosphate dehydrogenase (IMPDH) (HCV NS5B and IMPDH)

The Hepatitis C virus (HCV) nonstructural protein 5B (NS5B) is an RNA-dependent RNA polymerase (RdRp) essential for the replication of the viral RNA genome, making it a primary target for direct-acting antiviral (DAA) therapies (Source: UniProt P26664). Host inosine monophosphate dehydrogenase (IMPDH) is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides, which provides the necessary GTP building blocks for viral replication (Source: UniProt P20839). Drugs such as ribavirin utilize a multi-modal strategy by inhibiting IMPDH to deplete host guanosine pools while also interfering with NS5B-mediated synthesis, often acting as a mutagen that leads to 'error catastrophe' in the virus (Source: NIH PubChem). This dual targeting of a viral enzyme and a host metabolic pathway was a foundational approach in early HCV treatments to maximize antiviral efficacy and reduce the emergence of resistance. While modern DAAs like sofosbuvir are highly specific to NS5B, the modulation of host nucleotide pools remains a significant pharmacological mechanism in broader antiviral research.

Other names

HCV RNA-dependent RNA polymeraseNS5B polymeraseIMPDHInosine-5-monophosphate dehydrogenaseGuanosine nucleotide poolsHCV RdRp

Inhibition of the viral RNA-dependent RNA polymerase (NS5B) prevents the synthesis of the HCV RNA genome. Simultaneously, inhibition of the host enzyme inosine monophosphate dehydrogenase (IMPDH) depletes intracellular guanosine triphosphate (GTP) pools, which are necessary substrates for viral RNA synthesis and can lead to lethal mutagenesis of the viral genome (Source: PubMed PMID: 11553816, 15771579).